CoChat

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

Open access
Isa, Reiko, Horinaka, Mano, Tsukamoto, Taku, Mizuhara, Kentaro, Fujibayashi, Yuto, Taminishi-Katsuragawa, Yoko, Okamoto, Haruya, Yasuda, Shusuke, Kawaji-Kanayama, Yuka, Matsumura-Kimoto, Yayoi, Mizutani, Shinsuke, Shimura, Yuji, Taniwaki, Masafumi, Sakai, Toshiyuki, Kuroda, Junya · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active in MM, and plays pivotal roles in cell proliferation and cell survival of myeloma cells regardless of the profiles of cytogenetic and genetic abnormalities. This study investigated the therapeutic efficacy and mechanism of action of dual blockade of two major PDPK1 substrates, RSK2 and AKT, in MM. The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation. Moreover, the dual blockade of RSK2 and AKT exerted robust molecular effects on critical gene sets associated with myeloma pathophysiologies, such as those with MYC, mTOR, STK33, ribosomal biogenesis, or cell-extrinsic stimuli of soluble factors, in HMCLs. These results provide the biological and molecular rationales for the dual-targeting strategy for RSK2 and AKT, which may overcome the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23062919

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Activities and the role of cell proliferation of RSK2 and AKT in human myeloma–derived cell lines (HMCLs): (A) Baseline activities of RSK, AKT, and related kinases examined by Western blot (WB) in six HMCLs and peripheral blood mononuclear cells (PBMCs). The expression level of ACTB was examined as the internal control. Expression levels relative to ACTB are shown below each band measured by densitometric analysis using Image-J software. (B,C) Growth inhibitory effects of BI-D1870 (C) or ipatasertib (D) in six HMCLs. Cells were seeded at 2 × 105 cells/mL and treated with various concentrations of BI-D1870 (C) or ipatasertib (D) for 48 h. The IC50 values of BI-D1870 for NCI-H929, OPM-2, KMS12-BM, KMS28-PE, AMO-1, and RPMI8226 cells were 4.00, 4.34, 3.88, 4.95, 3.14, and 4.09 μM, respectively, while those of ipatasertib for NCI-H929, OPM-2, KMS12-BM, and KMS28-PE cells were 0.95, 2.12, 0.81, and 0.79 μM respectively. (D) Effects of BI-D1870 and ipatasertib on their target molecules in NCI-H929 and OPM-2 cells. Cells were treated with either ipatasertib, BI-D1870, or their combination at the indicated concentrations for 48 h. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control.
Figure 1 Activities and the role of cell proliferation of RSK2 and AKT in human myeloma–derived cell lines (HMCLs): (A) Baseline activities of RSK, AKT, and related kinases examined by Western blot (WB) in six HMCLs and peripheral blood mononuclear cells (PBMCs). The expression level of ACTB was examined as the internal control. Expression levels relative to ACTB are shown below each band measured by densitometric analysis using Image-J software. (B,C) Growth inhibitory effects of BI-D1870 (C) or ipatasertib (D) in six HMCLs. Cells were seeded at 2 × 105 cells/mL and treated with various concentrations of BI-D1870 (C) or ipatasertib (D) for 48 h. The IC50 values of BI-D1870 for NCI-H929, OPM-2, KMS12-BM, KMS28-PE, AMO-1, and RPMI8226 cells were 4.00, 4.34, 3.88, 4.95, 3.14, and 4.09 μM, respectively, while those of ipatasertib for NCI-H929, OPM-2, KMS12-BM, and KMS28-PE cells were 0.95, 2.12, 0.81, and 0.79 μM respectively. (D) Effects of BI-D1870 and ipatasertib on their target molecules in NCI-H929 and OPM-2 cells. Cells were treated with either ipatasertib, BI-D1870, or their combination at the indicated concentrations for 48 h. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control.CC BY · PubMed Central
Figure 2 Combinatory effect of BI-D1870 and ipatasertib in HMCLs: (A) Isobolograms for the in vitro growth inhibitory effect by the combination of BI-D1870 and ipatasertib in NCI-H929, OPM-2, KMS-12-BM, and KMS-28-PE cells. X-axis and Y-axis indicate the fraction affected by BI-D1870 and ipatasertib, respectively. (B) Cells were treated with ipatasertib (1 μM) and/or BI-D1870 (2 μM) in NCI-H929, while with ipatasertib (1 μM) and/or BI-D1870 (2.5 μM) in OPM-2 for 48 h. Patient-derived myeloma cells were treated with ipatasertib (3 μM) and/or BI-D1870 (5 μM) for 48 h. (C–E) Anti-tumor effects of BI-D1870, ipatasertib, and their combination in HMCLs. Cells were seeded at 2 × 105 cells/mL and treated with ipatasertib (1 μM) and/or BI-D1870 (2 μM) in NCI-H929, while with ipatasertib (1 μM) and/or BI-D1870 (2.5 μM) in OPM-2 for 48 h, and then were subjected to flow cytometric analysis. DNA content was examined by propidium iodide (PI)-staining cells for cell cycle analysis (C). Induction of apoptosis was examined by double staining with Annexin-V and PI. Apoptotic cells were Annexin-V (+)/PI (−) and Annexin-V (+)/PI (+) populations (D). The proportion of apoptotic cells were shown. Mean value with standard deviation (S.D.) of triplicate data. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 2 Combinatory effect of BI-D1870 and ipatasertib in HMCLs: (A) Isobolograms for the in vitro growth inhibitory effect by the combination of BI-D1870 and ipatasertib in NCI-H929, OPM-2, KMS-12-BM, and KMS-28-PE cells. X-axis and Y-axis indicate the fraction affected by BI-D1870 and ipatasertib, respectively. (B) Cells were treated with ipatasertib (1 μM) and/or BI-D1870 (2 μM) in NCI-H929, while with ipatasertib (1 μM) and/or BI-D1870 (2.5 μM) in OPM-2 for 48 h. Patient-derived myeloma cells were treated with ipatasertib (3 μM) and/or BI-D1870 (5 μM) for 48 h. (C–E) Anti-tumor effects of BI-D1870, ipatasertib, and their combination in HMCLs. Cells were seeded at 2 × 105 cells/mL and treated with ipatasertib (1 μM) and/or BI-D1870 (2 μM) in NCI-H929, while with ipatasertib (1 μM) and/or BI-D1870 (2.5 μM) in OPM-2 for 48 h, and then were subjected to flow cytometric analysis. DNA content was examined by propidium iodide (PI)-staining cells for cell cycle analysis (C). Induction of apoptosis was examined by double staining with Annexin-V and PI. Apoptotic cells were Annexin-V (+)/PI (−) and Annexin-V (+)/PI (+) populations (D). The proportion of apoptotic cells were shown. Mean value with standard deviation (S.D.) of triplicate data. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY · PubMed Central
Figure 3 Molecular effects with apoptotic induction by BI-D1870, ipatasertib, and their combination: Cells were seeded at 2 × 105 cells/mL and treated with indicated concentrations of BI-D1870, ipatasertib, or both agents for 48 h. (A) Activities of Caspase-3/7, Caspase-8, and Caspase-9 of untreated and treated cells measured by Caspase-Glo assay systems. (B) WB analyses for the detection of processing of caspases and PARP. Black arrow head and white arrow head indicate cleaved form of PARP and cleaved form of Caspase-9, respectively. (C) WB analysis for the detection of the activation of BID and the induction of BIM in untreated and treated HMCLs. White arrow head and black arrow head indicate full length BID and truncated BID, respectively. N.S.; no specific band. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control. (D) Transcriptional levels of BIM in treated cells relative to untreated cells. Mean value with S.D. of triplicate data. * p < 0.05, ** p < 0.01 *** p < 0.001, **** p < 0.0001.
Figure 3 Molecular effects with apoptotic induction by BI-D1870, ipatasertib, and their combination: Cells were seeded at 2 × 105 cells/mL and treated with indicated concentrations of BI-D1870, ipatasertib, or both agents for 48 h. (A) Activities of Caspase-3/7, Caspase-8, and Caspase-9 of untreated and treated cells measured by Caspase-Glo assay systems. (B) WB analyses for the detection of processing of caspases and PARP. Black arrow head and white arrow head indicate cleaved form of PARP and cleaved form of Caspase-9, respectively. (C) WB analysis for the detection of the activation of BID and the induction of BIM in untreated and treated HMCLs. White arrow head and black arrow head indicate full length BID and truncated BID, respectively. N.S.; no specific band. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control. (D) Transcriptional levels of BIM in treated cells relative to untreated cells. Mean value with S.D. of triplicate data. * p < 0.05, ** p < 0.01 *** p < 0.001, **** p < 0.0001.CC BY · PubMed Central
Figure 4 Gene expression change induced by BI-D1870, ipatasertib, or their combination in HMCLs: (A) Expression changes in all investigated genes relative to vehicle cells in NCI-H929 (X-axis) and OPM-2 cells (Y-axis). (B) Venn diagrams for numbers of commonly significantly upregulated (left) and downregulated (right) genes in NCI-H929 and OPM-2 cells. (C) Clustering of significantly modulated genes after treatment in NCI-H929 and OPM-2 cells.
Figure 4 Gene expression change induced by BI-D1870, ipatasertib, or their combination in HMCLs: (A) Expression changes in all investigated genes relative to vehicle cells in NCI-H929 (X-axis) and OPM-2 cells (Y-axis). (B) Venn diagrams for numbers of commonly significantly upregulated (left) and downregulated (right) genes in NCI-H929 and OPM-2 cells. (C) Clustering of significantly modulated genes after treatment in NCI-H929 and OPM-2 cells.CC BY · PubMed Central
Figure 5 Functional assessment of gene sets significantly modulated either by BI-D1870, ipatasertib, or their combination in HMCLs: (A) Plots for top 3 significantly enriched gene sets, MYC_UP.V1_UP (left), CSR_LATE_UP.V1_UP (middle), and MTOR_UP.N4.V1_UP (right) (www.gsea-misgdb.org/gsea/index.jsp, accessed on 1 December 2021), consisted of genes downregulated by the combination of BI-D1870 and ipatasertib in NCI-H929 and OPM-2 cells. (B) List of downregulated gene sets that are more significantly enriched by the combination treatment of BI-D1870 and ipatasertib compared to the treatment by either BI-D1870 or ipatasertib alone. Significance was shown by false discovery rate (FDR)(q-value) scores. −log10(FDR-q-value) score bigger than 1.3 is significant. (C) Plots for top 3 significantly enriched gene sets, MTOR_UP.N4.V1_DN (left), STK33_SKM_UP (middle), and MYC_UP.V1_DN (right) (www.gsea-misgdb.org/gsea/index.jsp, accessed on 1 December 2021), consisted of genes upregulated by the combination of BI-D1870 and ipatasertib in NCI-H929 and OPM-2 cells. (D) List of upregulated gene sets that are more significantly enriched by the combination treatment of BI-D1870 and ipatasertib compared to the treatment by either BI-D1870 or ipatasertib alone. Significance was shown by FDR(q-value) scores. -log10(FDR-q-value) score bigger than 1.3 is significant.
Figure 5 Functional assessment of gene sets significantly modulated either by BI-D1870, ipatasertib, or their combination in HMCLs: (A) Plots for top 3 significantly enriched gene sets, MYC_UP.V1_UP (left), CSR_LATE_UP.V1_UP (middle), and MTOR_UP.N4.V1_UP (right) (www.gsea-misgdb.org/gsea/index.jsp, accessed on 1 December 2021), consisted of genes downregulated by the combination of BI-D1870 and ipatasertib in NCI-H929 and OPM-2 cells. (B) List of downregulated gene sets that are more significantly enriched by the combination treatment of BI-D1870 and ipatasertib compared to the treatment by either BI-D1870 or ipatasertib alone. Significance was shown by false discovery rate (FDR)(q-value) scores. −log10(FDR-q-value) score bigger than 1.3 is significant. (C) Plots for top 3 significantly enriched gene sets, MTOR_UP.N4.V1_DN (left), STK33_SKM_UP (middle), and MYC_UP.V1_DN (right) (www.gsea-misgdb.org/gsea/index.jsp, accessed on 1 December 2021), consisted of genes upregulated by the combination of BI-D1870 and ipatasertib in NCI-H929 and OPM-2 cells. (D) List of upregulated gene sets that are more significantly enriched by the combination treatment of BI-D1870 and ipatasertib compared to the treatment by either BI-D1870 or ipatasertib alone. Significance was shown by FDR(q-value) scores. -log10(FDR-q-value) score bigger than 1.3 is significant.CC BY · PubMed Central
Figure 6 WB for MYC, mTOR, and p-mTOR: Cells were treated for 48 h at the indicated concentrations of agents. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control.
Figure 6 WB for MYC, mTOR, and p-mTOR: Cells were treated for 48 h at the indicated concentrations of agents. Expression levels relative to control (untreated cells) are shown below each band measured by densitometric analysis using Image-J software. ACTB was used as an internal control.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 11

Metadata

Authors
Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., Mizutani, S., Shimura, Y., Taniwaki, M., Sakai, T., & Kuroda, J.
Affiliations
  • Kyoto Prefectural University of Medicine (JP)
  • Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
Corresponding author
Kuroda, Junya
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-03-08
Volume
23
Issue
6
Pages
2919
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4220992956
Cited by
11
References
67
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 1
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Japan Society for the Promotion of Science (19K08872)
  • The Japanese Society Hematology Research Grant (N.A.)
  • The Japan Leukemia Research Fund Award (N.A.)
  • Japan Agency for Medical Research and Development (JP19ck0106516h0001)
  • Japanese Society for Myeloma Research Award (N.A.)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, RSK2, Akt, PDPK1, dual-targeted therapy, BI-D1870, ipatasertib, AGC kinases, apoptosis, building information modeling, Bid, c-Myc, mTOR, STK33, ribosome biogenesis, cytogenetic heterogeneity, combination therapy
MeSH terms
Humans, Multiple Myeloma, Protein Serine-Threonine Kinases, Ribosomal Protein S6 Kinases, 90-kDa, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, 3-Phosphoinositide-Dependent Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. https://app.cochat.ai/papers/10.3390/ijms23062919
The paper
Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., Mizutani, S., Shimura, Y., Taniwaki, M., Sakai, T., & Kuroda, J. (2022). The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23062919

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.